Unexpected Paths to IP Law with Dan Young and Colin White
Compliance Needs are Alive and Well: FTC's Recent Enforcement Activity
Innovation in Compliance: The Critical Importance of Mobile Application Security: Insights from Subho Halder
The LathamTECH Podcast — Getting Deals Done: Tackling Antitrust Challenges in Tech M&A
Compliance into the Weeds: Autonomous AI Whistleblowing Misconduct
Daily Compliance News: June 4, 2025, The Climate Disaster Management Edition
The Future of Supply Chains: Chris Andrassy on Using AI to Predict & Prevent Disruptions
Daily Compliance News: June 2, 2025, The Unintended Consequence Edition
How IP Can Fuel Your Startup's Growth
Inside a $175M Deal: Tim McLoughlin & Joshua Hayes Live From RDU Startup Week
Daily Compliance News: May 21, 2025, The I Want You Back Edition
Upping Your Game: Episode 3 - Embedded Compliance: From Gatekeeper to Business Enabler
State AG Pulse | Massive Google Settlement Shows AGs Serious About Privacy
Regulatory Ramblings: Episode 69 - Human Intelligence vs. Machine Judgment with Nigel Morris-Cotterill and Patrick Dransfield
From Cell Phones to Tractors: The Right to Repair Movement Drives On — Regulatory Oversight Podcast
Innovation in Compliance: Exploring the Intersection of Compliance, Technology, and AI with Ben Sperry
Upping Your Game: Episode 1 – Meeting Hui Chen’s Challenge
Compliance Tip of the Day: AI and Compliance Education
Sunday Book Review: April 27, 2025, The Books on Business for May Edition
The Briefing: The Future of TV? A 2025 Digital Media Trends Analysis
In the recently released 2025-2026 Budget, the Hong Kong Government has mentioned that it will further strengthen the city’s role as a leading international financial centre. It extends various favorable policies and reforms...more
From 31 March 2023, the listing framework will include innovative companies in frontier industries, creating more opportunities for investors in the Hong Kong capital market. The Stock Exchange of Hong Kong Limited (the...more
Like other global financial centers, Hong Kong has seen falling IPO volumes and volatile markets in 2022 in the face of challenging macroeconomic conditions and rising geopolitical tensions, including between China and the...more
In Short - The Situation: Hong Kong currently falls behind the United States and Mainland China in terms of the number and market capitalization of companies belonging to the "Specialist Technology Industries."...more
In an effort to close the gap with the U.S. and Mainland China in terms of the number and market capitalization of publicly listed companies in certain advanced or new technology industries, on October 19, 2022, the...more
The Hong Kong Stock Exchange (HKEx) has issued its much-anticipated consultation paper on creating a listing regime for Specialist Technology Companies (STCs) under proposed Chapter 18C of the HKEx listing rules, with a view...more
Market capitalisation, research and development investment, and historical financing would be the primary bases for listing such companies under the new proposal. On 19 October 2022, The Stock Exchange of Hong Kong...more
Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more
In April 2018, the Hong Kong Stock Exchange’s (HKEx) rule amendments permitting the listing of innovative, high-growth companies with dual-class share structures and pre-revenue biotech companies went into effect. The...more
The DOJ has charged former VW chief exec Martin Winterkorn (and 5 others) with conspiring to defraud the US government in Volkswagen’s “yearslong effort to rig its diesel vehicles to feign compliance with federal emissions...more
After publishing the “New Board Concept Paper Conclusions” in December 2017, the Stock Exchange of Hong Kong Limited (the Exchange) issued on 23 February 2018 a consultation paper entitled “A Listing Regime for Companies From...more
The Situation: The Hong Kong Stock Exchange’s failure to recognize that investors are able to evaluate biotech companies in the pre-revenue stages, and its consequent refusal to list those companies for trading, is viewed by...more